PMD Solutions is an emerging leader in prediction of respiratory compromise for both acute and community based patients. Leveraging our innovation RespiraSense, offering continuous and motion tolerant respiratory rate monitoring, we are improving clinical decision making of healthcare providers. To both detect deterioration early so that timely intervention can lead to improved outcomes, in addition to aiding in the safe and efficient early discharge of patients.
The challenge today is manual measurement of respiratory rate is prone to high degree of error with 80% of rates being incorrect, leading to over 40% of patient NEWS records incorrectly stating the level of their deterioration.
As the market leader in Ireland with RespiraSense used in over 23 hospitals and 47 clinical respiratory wards, PMD is working with the Irish Healthcare Services and Department of Health to co-design an integrated care solution where early discharge is coupled with hospital avoidance in the community for severe COPD patients.
Evidence to date is that RespiraSense predicts desaturation 12 hours before hypoxic events occur (SpO2 <92%), and before pyrexic events occur (Temp >38 degrees) [McCartan2021]. In addition, preventing 100% of community lead hospitalisations in Gold D stage COPD patients over the course of 12 weeks, returning 300% ROI, improving quality of life by 24% and empowering the patient to self manage their condition as a central partner in their care [Doherty 2022]. Ongoing evidence is also indicating that Respirasense predicts changing Arterial Blood Gases with >90% Positive Predictive Value [30% recruitment to date]
PMD is focused on #MakingEveryBreathCount with forward looking partners in delivering an evidence based enhanced quality of care. Find out more at www.pmd-solutions.com and @PMD_Respiratory or contact us on email@example.com.